A consortium led by Hemostatics receives €2.5 M to validate a revolutionary therapy against disabling and lethal haemorrhage

A public-private consortium formed by the biotech Hemostatics, based at the Barcelona Science Park, the Clínica Universidad de Navarra (CUN) and the Institut Català d'Investigació Química (ICIQ), has received 2.5 million euros from AEI, the State Investigation Agency, under the call for grants for Public-Private Collaboration Projects, to accelerate the development of an innovative treatment aimed at controlling disabling and lethal haemorrhage.

The aim of the project, led by Hemostatics - a spin-off from Cima Universidad de Navarra, attached to the CUN - is the preclinical and clinical development of the antifibrinolytic agent CM-352, a first-in-class drug that represents a pioneering therapeutic approach to control severe bleeding in unmet medical needs, such as those associated with major surgery, trauma or intracranial haemorrhage (ICH).

The CM-352 compound is the result of a long research process led by Dr Josune Orbe (CSO of Hemostatics), head of the CIMA's Atherothrombosis research group, and Dr José Antonio Páramo (CMO) of the Hematology Service of the Clínica Universidad de Navarra and member of the Spanish Society of Thrombosis and Haemostasis (SETH).

Based on a technology transfer and exclusive patent licensing agreement, Hemostatics was born in 2020, promoted by CIMA and a team of experts from the health and business sector, led by Dr Orbe, Dr Páramo and Nicolas Saglio, CEO of Hemostatics and managing partner at biomedical innovation consultancy HealthTech180, with more than 20 years' experience in strategic consulting and innovation for technology and healthcare companies.

Until now, the total capital raised to develop the compound amounts to €3M, including €0,3 M from the CDTI's Neotec programme received in 2022, plus other private funds.

A global health and economic issue
Haemorrhage accounts for up to 50% of trauma deaths occurring worldwide within 24 hours of traumatic injury, according to SEMICYUC-Spanish Society of Intensive and Critical Care Medicine and Coronary Units, and up to 80% of intraoperative trauma mortality. It is a very common complication in cardiovascular patients, or patients with certain rare genetic diseases, as well as in different clinical situations, such as surgeries, or postpartum haemorrhage, which is estimated to affect 14 million women each year and represents the world's leading cause of maternal death, according to WHO, with some 70,000 deaths annually.

"The socio-economic cost of acute bleeding in trauma cases alone is enormous and causes more than 6 million deaths per year (more than all communicable diseases combined, including COVID-19, malaria, tuberculosis, HIV/AIDS, etc.), and is responsible for a total cost of over $670 billion in the United States alone. However, an antihaemorrhagic agent, that can address the unmet medical needs of severe haemorrhagic processes and minimise the risk of possible side effects in the face of less severe haemorrhagic episodes, has not yet been found," reveals Nicolas Saglio. "Our compound, CM-352, in addition to reducing this major burden of morbidity and mortality, will significantly reduce the healthcare cost of annual expenditure on blood and transfusion-related activities".

Public-private partnership to create a next generation antifibrinolytic
CM-352 is a drug with a completely innovative mechanism of action, as it targets cessation of bleeding by inhibiting matrix metalloproteinases (MMPs), a revolutionary pharmacological strategy that promises to be more effective and safer than the current standard antifibrinolytics (TXA and EACA) used in clinical practice to control acute bleeding.

The regulatory preclinical phase will be coordinated by Hemostatics and will involve the integration of the efforts of the Atherothrombosis Research Group (CIMA), led by Dr Josune Orbe, the UT Health University of Houston and other organizations.

"We already have experimental results indicating that CM-352 is highly effective in all major bleeding scenarios, with no signs of toxicity, thrombosis, or off-target adverse effects. We will now complete efficacy, toxicity, pharmacodynamic and pharmacokinetic studies in several preclinical models required by regulatory agencies. Obtaining these results will allow us to reach a key milestone of the project: approval from the health authorities to test CM-352 in a phase I clinical trial. Our initial focus will be on the US FDA. Subsequently, we will also go to the EMA in Europe, and everything will be done in close collaboration with the Spanish agency, the AEMPS," Saglio explains.

Through the Innovation and Valorisation Laboratory and the High Throughput Experimentation (HTE Laboratory), the ICIQ will address the identification and optimisation of a CM-352 synthesis route that improves the efficiency and reduces the cost of the production process of the molecule. The team involved in the project will be led by Dr. Fernando Bravo, manager of the Knowledge and Technology Transfer Department (KTT) and Industrial Projects, and Dr. Xisco Caldentey, manager of HTE.

"Our objective will be to evaluate the tolerance and safety of CM-352 in patients undergoing scheduled total knee replacement surgery (total knee arthroplasty) to prevent possible hemorrhagic complications, which constitute a serious associated adverse event. This represents a very important milestone in the compound's development since, in existing literature, no clinical study has reported the use of MMP inhibitors to treat hemorrhages. The absence of toxicity and secondary effects after treatment with CM-352 will also represent the first time such results are obtained for an MMP inhibitor in humans, allowing us to move to a Phase II focused on severe hemorrhages in traumatology, where there is currently no treatment with proven clinical efficacy",, says Dr. Bravo.

Finally, the CM-352 phase I trial will involve the active participation of CUN, with technical support from CIMA and will focus on severe haemorrhage in traumatology, where there is no treatment with proven clinical efficacy. The study will be carried out by the Haemostasis and Thrombosis Unit of the Haematology Department and the Department of Orthopaedic Surgery, under the coordination of Dr José Antonio Páramo.

"Our objective will be to evaluate the tolerance and safety of CM-352 in patients undergoing scheduled total knee replacement surgery (total knee arthroplasty) to prevent possible hemorrhagic complications, which constitute a serious associated adverse event. This represents a very important milestone in the compound's development since, in existing literature, no clinical study has reported the use of MMP inhibitors to treat hemorrhages. The absence of toxicity and secondary effects after treatment with CM-352 will also represent the first time such results are obtained for an MMP inhibitor in humans, allowing us to move to a Phase II focused on severe hemorrhages in traumatology, where there is currently no treatment with proven clinical efficacy", noted Dr. Páramo.

This project (Ref. CPP2022-009643) is funded by MICIU/AEI/ 10.13039/501100011033 and by the "European Union NextGenerationEU/PRTR".

Barcelona Science Park
c/ Baldiri Reixac 10, Ed. Clúster, 1a planta
08028 Barcelona

Tel. 34 934 034 574
e-mail: comunicacio@pcb.ub.cat

The Parc Científic de Barcelona is one of Europe's model ecosystems in research, technology transfer and innovation, covering a built-up surface area of more than 100,000 m² with some 3,000 professionals working mainly in the health sector: pharmacology, biotechnology, medical technologies, food and cosmetics.

Located in Barcelona, ​​the Park features more than 30,000 m2 of laboratory and office space that it leases out, coupled with an extensive range of scientific services on offer in the domain of the life sciences. The Park was built by the University of Barcelona in 1997, becoming the first science Park in Spain.

This release was published on openPR.